Milestone Capital manages the Milestone China Opportunities Fund I, L.P., the Milestone China Opportunities Fund II, L.P., the Milestone China Opportunities Fund III, L.P. (the “Funds”), as well as the Milestone Kunshan Investment Fund, L.P. (the “RMB Fund”) which invest primarily in established high-growth companies seeking expansion or acquisition capital in China. The Funds seek to maximize medium to long term capital appreciation by making direct investments to acquire minority or majority equity stakes in those companies identified by Milestone’s investment team. The Funds’ investment size typically ranges between US$ 10 million to US$ 100 million. The RMB Fund’s investment size ranges between RMB 20 million to RMB 80 million. The Funds invest in a limited number of portfolio companies where the Milestone Capital team can dedicate significant resources to each portfolio company.  Milestone Capital’s success formula is predicated on proprietary deal flows, professional due diligence, disciplined investment approach, creative structuring and proactive monitoring with a focus on value creation. Milestone Capital usually requires board representation and stringent shareholder protection commensurate with its shareholding.  Milestone Capital has a strong track record in helping portfolio companies list on either domestic or foreign stock exchanges. We leverage our extensive network of advisors, industry executives, portfolio companies as well as business relationships to bring superior value-added support to our portfolio companies from both financial and strategic angles.

Milestone Capital China

Kleiner Perkins is a venture capital firm specializing in investing in early-stage, growth, and incubation companies. The firm continues that legacy, investing in founders with bold ideas that span industries and continents, partnering with them from inception to IPO and beyond to maximize the potential of their ideas. They also focus on early computer firms using their devices and programming and service companies. It also invests in the digital, life sciences, and healthcare industries.

Kleiner Perkins

CDIB pioneered venture capital and investment banking in Taiwan and today it remains the predominant leader in venture capital business in Taiwan with a market share of over 30%. Along with Taiwan's industrial development, CDIB has built up a wealth of experience in high-tech investment while its investment overseas has extended to the US, Japan, Korea and S.E. Asia.

China Development Industrial Bank (CDIB)

Biomark Capital provides venture funding and assistance to early, mid, and late-stage life science companies. We target companies with novel approaches to diagnostics, therapeutics, medical devices, and digital health that will change the face of healthcare innovation in the future.  We share the drive and vision of our portfolio companies to collaborate with them in accelerating growth and building successful business ventures. Biomark Capital was previously known as GBP Capital.

Biomark Capital

Suzhou Industrial Park Bioventure Investment Management Limited (Bioventure) was established in September 2013. Bioventure its first element of the new bio-industry funds 540 million yuan fund size. Bioventure specialize in the field of life sciences in the early stages of the venture capital investments as having high strength and growth, greater development space, excellent management team, biotechnology, drug discovery, medical devices and healthcare services companies, and provide capital, management , operation and other aspects of post-investment support and services.  Bioventure brought together senior investment professionals team with bio-pharmaceutical industry investment experience, strong fund management, entrepreneurship and venture capital and operating experience in business, have a deep understanding of the domestic and foreign markets, capable of its forward-looking international perspective and extensive The industry has the potential resources to help innovative companies grow rapidly and gain greater success, while giving fund investors bring considerable returns.  Suzhou Industrial Park, the core investor BioBay has the country's best medical and pharmaceutical incubator function, use the platform, the project team has great resources and industrial service advantages, Yuan-sheng venture has successfully invested in 20 projects have been cast projects in their own development and follow-up financing, has made outstanding achievements in the industry for all to see, and won the Venture's trust and praise.  By focusing and extensive industry resources, Bioventure determined to become one of China's most successful medical and pharmaceutical venture fund. Bioventure expectations and in the medical and pharmaceutical industry where there joint venture development cooperation.

BioVenture

Liwick Investment Management

Sanofi offers research, development, manufacturing, and marketing of innovative therapeutic solutions. It covers areas such as diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health, and the new G enzyme.

Sanofi

Eden Biologics

Eden Biologics, formerly known as JHL Biotech (''JHL'') , is a biopharmaceutical company that develops biosimilars and accelerates the development programs for clients & partners through the provision of contract development and manufacturing services. We are specialists in manufacturing biologics, from cell line development to commercial manufacturing with both global and regional regulatory affairs expertise.

Eden Biologics, Inc. is a biopharmaceutical company based in Hsinchu, Taiwan, focusing on biosimilar development and biologics contract development and manufacturing. The company was formerly known as JHL biotech and rebranded to Eden Biologics in February 2021. Eden Biologics specializes in developing biosimilars, with a pipeline portfolio of over 13 products as of July 2022. Their leading biosimilar program, EB1001 (a denosumab biosimilar), entered Phase 3 clinical trials in 2021. The company's expertise includes the development of cell lines for protein drug production, upstream and downstream process development and analysis, quality control and inspection specifications establishment, and cell bank generation.

Bora Pharmaceuticals acquires Eden Biologics CDMO Assets

Eden Biologics finalizes sale of CDMO assets to Bora

Bora Pharmaceuticals acquires CDMO assets from Eden Biologics

Bora bolsters CDMO biz with Eden buy

Bora scoops up plant from Eden, the company at the center of the Genentech theft saga

Bora Pharmaceuticals acquires Eden Biologics CDMO Assets Bora establishes a leadership position in Taiwan’s CDMO sector as it continues to expand into the global CDMO market

JHL Biotech Officially Changes Name to EDEN Biologics – Eden Biologics

Eden Biologics Statement – Eden Biologics

Eden Biologics – World

Bringing Life-Saving Biologics to More Patients

Biosimilars

Eden Biologics, Inc. is a biopharmaceutical company based in Hsinchu, Taiwan, focusing on biosimilar development and biologics contract development and manufacturing. The company was formerly known as JHL biotech and rebranded to Eden Biologics in February 2021. Eden Biologics specializes in developing biosimilars, with a pipeline portfolio of over 13 products as of July 2022. Their leading biosimilar program, EB1001 (a denosumab biosimilar), entered Phase 3 clinical trials in 2021. The company's expertise includes the development of cell lines for protein drug production, upstream and downstream process development and analysis, quality control and inspection specifications establishment, and cell bank generation.
In July 2022, Eden Biologics completed the sale of its Contract Development and Manufacturing Organization (CDMO) business assets to Bora Pharmaceuticals. This transaction, valued at up to USD 65 million, included the transfer of Eden's CDMO facility located in Hsinchu Biomedical Science Park, Taiwan. The facility was equipped with four 500L bioreactors certified by the EU Qualified Person and the Taiwan Food and Drug Administration.

Coherus BioSciences is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative immunotherapies for cancer treatment. The company's strategy revolves around building a leading immuno-oncology franchise funded by cash generated from its portfolio of FDA-approved therapeutics. Coherus markets several biosimilar products in the US, including UDENYCA (pegfilgrastim-cbqv), a biosimilar of Neulasta, CIMERLI (ranibizumab-eqrn), a biosimilar of Lucentis, and YUSIMRY (adalimumab-aqvh), a biosimilar of Humira.
In July 2023, Coherus launched YUSIMRY at a list price of USD 995 per carton for two 40 mg/0.8 mL autoinjectors, representing a discount of more than 85% compared to Humira. This pricing strategy aims to improve patient access to adalimumab treatment by offering significant cost savings. YUSIMRY is indicated for various autoimmune conditions, including rheumatoid arthritis, psoriatic arthritis, and Crohn's disease.
Coherus is also developing toripalimab, an anti-PD-1 antibody, for the US and Canadian markets through a licensing agreement with Shanghai Junshi Biosciences Ltd. A Biologics License Application (BLA) for toripalimab in combination with chemotherapy for treating recurrent or metastatic nasopharyngeal carcinoma was under FDA review.
In March 2024, Coherus reported net revenue of USD 91.5 million for Q4 2023 and USD 257.2 million for the full year 2023, driven by sales of UDENYCA and CIMERLI. However, the company faced challenges, including a net loss of USD 79.7 million in Q4 and USD 237.9 million for the full year 2023. To address these challenges, Coherus initiated a workforce reduction of 30% to streamline operations and focus on oncology.

Coherus Biosciences

Custom Biologics is a Canadian contract research organization (CRO) specializing in bioanalytical services for biopharmaceuticals, vaccines, and cell and gene therapy products. With over 20 years of experience, the company focuses on designing and validating regulatory compliant assays for functional characterization, potency/bioactivity assessments, clinical pharmacokinetics, and immunogenicity of biotherapeutic drugs. Custom Biologics' genomics group develops molecular genetic assays for gene and genome analysis, measuring genetic inserts and transgenes in gene therapy vectors, oncolytic viruses, and nucleic acid-based vaccines. The company has also developed a proprietary isothermal nucleic acid amplification technology called DASL-RAPID for rapid identification of human and food-borne pathogens. Custom Biologics maintains a Health Canada cGMP Drug Establishment License and operates under a quality system based on FDA and EMEA GLP guidelines. The company's services are utilized in preclinical research and development programs, as well as for validated GMP-compliant assays suitable for stability analysis, clinical analysis, and clinical/market lot release testing. Custom Biologics employs state-of-the-art bioanalytical laboratory equipment and sophisticated statistical software to generate data for submissions to regulatory agencies worldwide.

Custom Biologics

CuriRx, Inc., founded in 2012, is a contract development and manufacturing organization (CDMO) based in Wilmington, Massachusetts. The company specializes in providing end-to-end support for biotherapeutic drug developers, focusing on complex molecules such as recombinant proteins, monoclonal antibodies, bispecific antibodies, vaccines, antibody drug conjugates, oligonucleotides, and gene therapy products. CuriRx's services encompass upstream and downstream process development, optimization, characterization, scale-up and scale-down, analytical development, formulation development, and lyophilization.
In January 2022, CuriRx launched its Advanced Bioprocessing and Analytical Center, which combines state-of-the-art bioprocessing laboratories with the CuriLytics Platform's high-resolution analytical instrumentation. This center aims to accelerate biotherapeutic drug development by leveraging the team's extensive bioprocessing experience and employing the latest methods in upstream and downstream process development. The CuriLytics Platform utilizes high-resolution mass spectrometry and various orthogonal characterization methods to further de-risk drug development.
CuriRx has the capacity to produce non-GMP vials for animal studies and non-GMP stability support studies. The company's key personnel have been involved in successful development projects for notable drugs such as HUMIRA, SYNAGIS, BLINCYTO, and GATTEX. In September 2013, CuriRx was awarded a five-year contract by the National Cancer Institute for the development and production of oncology products, demonstrating its expertise in the field.

CuriRx

Paras Biopharmaceuticals Finland Oy is a biopharmaceutical technology development company based in Oulu, Finland. Founded in 2012, the company specializes in the development and manufacturing of complex biologics and biosimilars using microbial expression systems. Paras Biopharmaceuticals operates a state-of-the-art 25,000 square foot biologics production facility in Finland, which includes 4,300 square feet of classified cleanroom space. The facility is equipped for media and buffer preparation, fermentation, harvest and extraction, purification, final filtration, and freeze-drying.
The company's core activities are divided into two main divisions: Paras Biopharma, which focuses on biologics Contract Development and Manufacturing Organization (CDMO) services, and Paras Biologics, which handles biosimilar development and licensing. Paras Biopharmaceuticals has developed proprietary technology platforms including Biomultifold, Noblecleav, and Cytofold StructQuant to achieve high productivity and quality in biologics manufacturing. These technologies enable the company to produce complex proteins and biosimilars cost-effectively at scale.
As of December 2022, Paras Biopharmaceuticals reported achieving success with "Continuous Biomanufacturing" for high-value onco-immunology and urology biosimilars. The company has also made advancements in maximizing recombinant protein expression in microbial systems, reporting expression levels of up to 12g/L or more of fully folded, biologically active protein in fermentation broth as of July 2023.

Paras Biopharmaceuticals

Kashiv Biosciences, LLC is a fully integrated biopharmaceutical company focused on developing biosimilars and specialty biopharmaceutical products. The company has global research and development, clinical, regulatory, and manufacturing capabilities. Kashiv utilizes its MayaBio reactor technology to develop biosimilars. The company's product portfolio includes biosimilars targeting conditions such as asthma, chronic idiopathic urticaria, and neutropenia. Kashiv's lead biosimilar candidate, ADL018, is a proposed biosimilar to Xolair (omalizumab) currently in Phase III clinical trials for chronic spontaneous urticaria. In March 2022, Kashiv received FDA approval for its first biosimilar RELEUKO (filgrastim-ayow), a biosimilar referencing Neupogen. The company has a robust pipeline of seven biosimilars and multiple 505(b)(2) and complex peptide generic products in development. Kashiv operates FDA-approved GMP manufacturing facilities in Chicago, Illinois and has state-of-the-art R&D infrastructure in Ahmedabad, India. The company is headquartered in Piscataway, New Jersey.
Key customers and partnerships
Kashiv has established strategic partnerships to commercialize its products globally. In October 2023, Kashiv entered into an exclusive licensing agreement with Alvotech for the development and commercialization of ADL018 in Europe, the UK, Australia, Canada, and New Zealand. In July 2024, Kashiv signed an exclusive licensing agreement with Amneal Pharmaceuticals for the commercialization of ADL018 in the US. Kashiv has also collaborated with Amneal on the development and commercialization of other biosimilars, including RELEUKO and FYLNETRA. These partnerships allow Kashiv to leverage its partners' commercial expertise and global reach to bring its biosimilar products to market.

Kashiv Biosciences

Biotechnology companies that focus on the research, development, production, and commercialization of prescription drugs including biosimilars.

Biotechnology companies that focus on the research, development, production, and commercialization of biosimilars based on original biological medicine.

Companies offering R&D capabilities and production facilities to biosimilar companies on contracts or partnerships.

Biopharmaceutical technology development and support service companies that offer specialized solutions to biosimilar companies.

Companies offering testing solutions to support the biological characterization, comparability, and other clinical assessments required in the biosimilar development process.

AI/ML-driven technology platforms support drug design and development process and integration of drug substance development

Eden Biologics

Sources

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless